Breast Cancer
We are pleased to announce Part 2 of the new 2-part series, Did You Know? Beyond the Data. Our second article, with video commentary by Hope Rugo, MD, and an accompanying infographic, presents clinical data and real-world evidence on treatment patterns and tolerability considerations for CDK4/6 inhibitors in patients with early breast cancer with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes. Read More ›
In honor of Breast Cancer Awareness Month, we explore the growing role of AI in breast cancer screenings. Read More ›
This device produces a 5-year risk score that is intended to complement current protocol of radiologists’ reviews. Read More ›
It’s Breast Cancer Awareness Month, and officials with the Department of Veterans Affairs (VA) are encouraging patients to be screened and perform regular self-checks. Read More ›
Only 19% of women said a healthcare provider had discussed nutrition’s role in breast cancer risk in a new Physicians Committee for Responsible Medicine/Morning Consult survey. Read More ›
A regular column that features the 2024 approvals and updates from the Food and Drug Administration. Read More ›
This feature examines some of the cutting-edge trials that have been launched throughout 2024 and that are actively recruiting in breast cancer. Read More ›
Breastfeeding after receiving treatment for breast cancer is safe, and women who
have a germline BRCA mutation do not face an increased risk of recurrence or developing new breast cancers, according to data presented last month at the ESMO 2024 Congress. Read More ›
Invasive breast cancer will be diagnosed in an estimated 300,000 American women in 2023. Early screening and targeted treatment have improved overall survival since the late 1980s, but breast cancer remains the second most common cause of cancer death in women, occurring in 1 in 39 women. Read More ›
Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results of the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›